Guardant Health posted a non-GAAP loss of $0.29 per share for the third quarter. That matched consensus but fell a penny short of the Earnings Whisper number of -$0.28, a 3.6% miss against the more demanding bar. Revenue told a cleaner story. Sales of $360.98 million beat the $350.83 million consensus by 2.9% and grew 36.1% year over year, up from roughly $335 million in the second quarter. Earnings improved 32.6% as the adjusted loss narrowed from $0.39 a year ago. The penny shortfall matters less than what drove the top line. Shield is scaling faster than management planned, and the full-year revenue outlook has now been raised for the third consecutive quarter, to $1.36 billion to $1.37 billion. The company described the new range as in line with estimates rather than ahead of them.

The quality of the quarter depends on which earnings line you read. On a non-GAAP basis, losses narrowed. Adjusted EBITDA loss improved to $37.3 million from $45.5 million a year earlier and from about $56 million in the second quarter. Free cash burn of $37.2 million was roughly half of the second quarter's $70 million. GAAP results moved the other way. The net loss widened to $124.4 million, or $0.93 per share, from $0.74. Stock-based compensation and related payroll costs rose to $66.3 million from $43.5 million, and a $19 million "other" item sat in G&A. Weighted shares also climbed about 8% year over year. Non-GAAP operating expenses rose 26% as the company kept building out Shield's commercial infrastructure. Investors focused on per-share value should not let the adjusted improvement obscure the dilution and GAAP losses underneath.

Screening was the engine. Shield revenue jumped 180% to $67.6 million on 83,000 tests, up from 66,000 in the second quarter and 44,000 in the first. Management said average selling price held above $800. Covered lives rose to roughly 100 million, or more than 80% of the eligible market, from about 70 million last quarter. The gains came from Carelon, EviCore, UnitedHealth and several regional plans, plus a Pennsylvania law eliminating cost-sharing for blood-based colorectal screening. The most consequential operating datapoint may be cost per test. It fell to $330 from $410 in the second quarter, beating the $350 year-end target a quarter early. That helped lift full-year non-GAAP gross margin guidance to 65%, the top of the prior range, and quarterly non-GAAP gross margin reached 67%.

The central tension is in Oncology. Test volume grew 58% to 117,000, yet Oncology revenue rose only 25%, down from 38% in the second quarter and 36% in the first. Revenue growing at less than half the pace of volume means revenue per test is falling. The full-year Oncology revenue guide stayed at about 30% even as the volume outlook moved above 50%. Biopharma & Data also slowed to 8% growth from 17% in the first quarter. Bears have legitimate ammunition here. The legacy franchise funding the Shield build is growing volume faster than dollars, while the opex guide was raised again to $1.105 billion to $1.125 billion.

The catalyst pipeline is substantial, though several items are still pending:

• The FDA approved Guardant360 CDx as the companion diagnostic for AstraZeneca's camizestrant, the first liquid-biopsy CDx approval for longitudinal testing in breast cancer. However, quarterly testing does not yet align with the current national coverage determination and relies on a pharma stopgap.
• The company filed a PMA for Guardant360 Tissue, with approval expected around 2027.
• An ADLT application for the Liquid CDx is on track for the first half of 2027.
• Reveal Ultra is slated for clinical launch by year-end.

On the risk side, full-year free cash burn guidance widened to $205 million to $220 million. Management attributed this to a CMS claims-processing delay on the new billing code that pushes $10 million to $15 million into 2027. Management also expects Shield pricing to drift lower as the commercial mix rises, and UnitedHealthcare pricing has not yet been negotiated.

Investors did not enter the report with much enthusiasm. Earnings Whispers sentiment slipped from slightly positive (0.04) to modestly negative (-0.14), a meaningful cooling though not a capitulation. Shares sat at $168.58 heading into the release, up 3.7% from the open after the July report. That is 28.4% above the 200-day moving average but 11.8% below the $191.05 52-week high set on October 6. The stock had already given back a good portion of its early-October run, even as the Earnings Whispers trend readings stayed mostly positive on sequential growth and momentum.

The bottom line is that Guardant delivered a credible beat-and-raise on revenue. Shield volume, coverage and unit costs are all moving faster than management's own targets. The penny miss versus the whisper and the timing-driven cash-burn widening are minor blemishes. The harder question is Oncology: volume is booming while revenue growth has decelerated sharply. Until reimbursement milestones such as the ADLT and the updated coverage determination restore pricing, the story rests increasingly on Shield carrying the growth while operating expenses and dilution keep rising.